<SUBMISSION>
<ACCESSION-NUMBER>0001144204-03-004142
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20030801
<ITEMS>5
<ITEMS>7
<FILING-DATE>20030804
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<IRS-NUMBER>51040241
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>03819782
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>doc1.txt
<TEXT>
<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest reported)           August 1, 2003
                                           -------------------------------

                           Advanced Biotherapy, Inc.
                          ---------------------------
             (Exact name of registrant as specified in its chapter)

   Delaware                       0-26323                51-0402415
------------------            ----------------    -----------------------
(State or other jurisdiction    (Commission           (IRS Employer
      of incorporation)         File Number)       Identification No.)

6355 Topanga Canyon Boulevard, Suite 510                            91367
----------------------------------------                            -----
Woodland Hills, California                                       (Zip Code)
--------------------------
(Address of principal executive offices)

Registrant's telephone number, including area code   (818) 883-6716
                                                   --------------------



<PAGE>



Item 5.  OTHER EVENTS.

         The registrant published a press release on July 30, 2003 which
reported that Advanced Biotherapy, Inc. has entered into an agreement to conduct
joint clinical investigations with the Russian Federation Ministry of
Health/State Institute of Transplantation and Artificial Organs..

Item 7.  FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

Designation       Description of Exhibit


10.13             Agreement for Joint Clinical Investigations between the State
                  Institute of Transplantation and Artificial Organs of the
                  Ministry of Health of the Russian Federation and Advanced
                  Biotherapy, Inc.

99.1     Press Release, dated July 30, 2003


                                   Signatures

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                               ADVANCED BIOTHERAPY, INC.
                               (Registrant)


Date:  August 1, 2003          By:      /s/Edmond Buccellato
                                        --------------------------------------
                                        Edmond Buccellato, President and CEO




                                INDEX TO EXHIBITS

      Exhibit               Description

      10.13       Agreement for Joint Clinical Investigations between the State
                  Institute of Transplantation and Artificial Organs of the
                  Ministry of Health of the Russian Federation and Advanced
                  Biotherapy, Inc.

      99.1        Text of Press Release, dated July 30, 2003



<PAGE>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>3
<FILENAME>doc2.txt
<TEXT>
<PAGE>


Exhibit 10.13
                   AGREEMENT FOR JOINT CLINICAL INVESTIGATIONS

Both sides note that the first treatment of autoimmune diseases by removal of
interferons (cytokines) was proposed in 1974 by Professor S.V. Skurkovich
(Nature, 1974;247:551-2). He also proposed to remove TNF-(alpha) in various
autoimmune conditions, including AIDS (J IFN & Cytokine Res 1989;9:S2 and other
publications and patents). The use of anticytokines in autoimmune conditions has
received wide experimental and clinical confirmation in various laboratories of
the world. As is known, organ transplant rejection is also connected with
autoimmune mechanisms. In joint investigations positive results were obtained
with the use of antibodies to interferon-(gamma) in corneal transplants
(Treatment of corneal transplant rejection in humans with
anti-interferon-(gamma) antibodies,. Am J Opthalmol 2002;133:829-30).

Based on this, the State Institute of Transplantation and Artificial Organs of
the Ministry of Health of the Russian Federation ("Institute" herein) in the
person of the Academician Russian Medical and Professor Valery Ivanovich
Shumakov and Advanced Biotherapy, Inc. (ABI- USA) in the person of Professor
S.V. Skurkovich, vice-president of ABI, agree to conduct joint clinical
investigations on the reduction or prevention of organ transplant rejection by
anticytokine therapy. In our joint investigation mainly anti-interferon-(gamma)
antibodies will be used after transplantation of the heart, lung, liver, or
pancreatic beta-islet cells.

Treatment of other conditions besides transplantation is possible.
ABI will supply the Institute with antibodies to interferon g and antibodies to
TNIF-(alpha) and laboratory reagents (immunological) monitoring in accordance
with a protocol for anticyotkine therapy.


[                                   REDACTED                                 ]

Publications of the results of the clinical trials will be done jointly. ABI has
the right to use the results of the trials as it wishes. The first publications
of the treatment of each condition will be in English and the first author will
be a representation of ABI. Later, if any Russian language reports are
published, the first authors will be members of the Institute.

If the Institute wishes to send a representative to a conference outside of
Russia to present the results of the clinical testing, ABI will pay expenses
(registration, travel and hotel) for one attendee per conference.

This agreement is made and signed in English and Russian languages and has the
same validity.


/s/Simon Skurkovich                /s/Valery Ivanovich Shumakov
-------------------------          ------------------------------------------
on behalf of                       on behalf of
Advanced Biotherapy, Inc.          the State Institute of Transplantation and
                                   Artificial Organs of the Ministry of Health
                                   of the Russian Federation

<PAGE>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>doc3.txt
<TEXT>
<PAGE>


EXHIBIT 99.1

Press Release                                 Source: Advanced Biotherapy, Inc.

Advanced Biotherapy Inc. Launches Program to Study Antibody Therapy in Treating
Organ Transplant Rejection Wednesday July 30, 8:43 pm ET

Announces Joint Clinical Investigation Agreement with Russia's Leading
Transplant Center

LOS ANGELES--(BUSINESS WIRE)--July 30, 2003-- Advanced Biotherapy Inc.
(OTCBB:ADVB - News) -- a developer of new antibody therapies for treating severe
and widespread autoimmune diseases -- today announced that it has entered into
an agreement to conduct joint clinical investigations with the Russian
Federation Ministry of Health/State Institute of Transplantation and Artificial
Organs. Under the agreement, the Institute will conduct human studies on select
organ transplant patients using Advanced Biotherapy's investigational antibody
therapies. The objective of the joint investigation is to evaluate the Company's
antibody therapies in preventing or halting organ transplant rejection.

Advanced Biotherapy's antibody therapies are based on a pioneering theory first
published nearly three decades ago in the journal Nature by Simon Skurkovich,
M.D., Ph.D., D.Sc. -- the Company's director of research and development. Since
it was first proposed, the concept of neutralizing the body's overproduction of
certain immunomodulator substances to treat autoimmune diseases has achieved
wide support in the international scientific community and has achieved
commercial viability.


Autoimmune diseases are the result of an inappropriate immune response in which
the body's immune system attacks healthy cells and organs. Certain chemicals
called cytokines are hyperproduced, which brings about the autoimmune condition.
One of Advanced Biotherapy's antibody therapies is designed to remove or
neutralize these excessive cytokines known as gamma interferon and tumor
necrosis factor-alpha, induced by gamma interferon.


Removal of these agents is associated with therapeutic effects, and could
possibly be a universal treatment for certain types of autoimmune diseases.
Advanced Biotherapy has already achieved encouraging results in clinical trials
in rheumatoid arthritis, multiple sclerosis, various autoimmune skin diseases
(psoriasis, alopecia areata, vitiligo, pemphigus, epidermolysis bullosa), and
others.


"As a result of our strong patent position and the very promising
investigational clinical study results we have already achieved in a number of
autoimmune conditions at various well-respected research institutes in Moscow,
Russia, as more specifically reported by the Company in its recent Securities
and Exchange reports, we have accepted an invitation from Russia's leading
transplant institute to conduct human studies," says Ed Buccellato, Advanced
Biotherapy's CEO. "The State Institute of Transplantation and Artificial Organs
is Russia's largest transplant center. It conducts more than 100 kidney
transplants alone each year, in addition to heart, liver and lung transplants.
It is now known that the body reacts to organ and cell transplantation in much
the same way it reacts to an autoimmune disease. The Company maintains that
treatment for organ transplant rejection can be similar to treatment for
autoimmune diseases."


In a previous joint clinical investigation conducted at the Research Institute
of Eye Diseases of the Russian Academy of Medical Sciences, positive results
were obtained with the use of Advanced Biotherapy's investigational antibodies
in patients suffering from corneal transplant rejection ("Treatment of Corneal
Transplant Rejection in Humans with Anti-Interferon-Gamma Antibodies," Am. J.
Ophthalmology 2002; 133:829-30). As reported, antibodies to interferon-gamma
halted corneal transplant rejection in all patients that were treated.



<PAGE>

The Company also recently performed investigational clinical testing at the
Research Institute of Pediatric Hematology of Russia of its anti-interferon
gamma antibody on several children with type I diabetes, an autoimmune disease.
Results of this study, allowing all patients to lower their daily insulin dose,
are scheduled to be presented in Berlin at the "8th International Workshop on
Autoantibodies and Autoimmunity" in September.


Mr. Buccellato further commented, "In the Institute's clinical investigations,
the Company's first project will be to administer our investigational antibodies
to gamma interferon and to tumor necrosis factor-alpha after transplant of
insulin-producing pancreatic beta cells in type I diabetic patients."


Mr. Buccellato added, "We also find it quite encouraging that a number of noted
U.S.-based biotechnology companies have, and continue, to conduct
investigational clinical trials in Russia."


About Advanced Biotherapy


Advanced Biotherapy, Inc. is pioneering the development of new antibody
therapies for treating severe and widespread autoimmune diseases. Its
investigational therapies attack autoimmune diseases at their source,
neutralizing biologic imbalances that impair immune system function. Core
technology is protected under U.S. patents and patents pending for the exclusive
use of a class of antibodies to the protein known as gamma interferon and to
tumor necrosis factor-alpha for treating a range of diseases. The company is
headquartered in Woodland Hills, California. www.advancedbiotherapy.com


Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated results or
other expectations expressed in our forward-looking statements. The risks and
uncertainties which may affect the development, operations and results of our
business include, but are not limited to the following: risks associated with
clinical trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory approval process, the risks of competitive
products, the risks of our current capital resources, the uncertainties as to
the availability of future capital and our future capital requirements, and the
risks associated with the extent and breadth of the Company's patent portfolio.
The foregoing discussion of the pending clinical investigations and the effect
of the patents issued and pending involves risks and uncertainties, including
but not limited to the risks that third parties may be successful in challenging
such patents; or that granted claims may be held invalid or interpreted
differently by a court of law; or that new technologies will be developed that
are superior in treating the diseases targeted by Advanced Biotherapy, Inc.
Readers are cautioned not to place reliance on these forward-looking statements,
which speak only as of the date the statements were made. See the Company's
public filings with the Securities and Exchange Commission for further
information about risks and uncertainties that may affect the Company and the
results or expectations expressed in our forward-looking statements, including
the section captioned "Factors That May Affect The Company" contained in the
Company's Annual Report on Form 10-KSB for the fiscal year ended December 31,
2002.


----------------------------
Contact:
     Advanced Biotherapy, Inc.
     Amy Buccellato, 818-883-6716
     www.advancedbiotherapy.com

<PAGE>

</TEXT>
</DOCUMENT>
</SUBMISSION>
